Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: crysball who wrote (421)	1/13/1999 9:16:00 PM
From: Cacaito	Respond to of 1386

ncbi.nlm.nih.gov There is already a study of Tamoxifen just for prevention of breast cancer, there is also an ongoing Tamoxifen vs Raloxifen recently announced study by the NIH solely for prevention of breast cancer and thousands of women are to be enrolled, dosing and side effects are part of the aim. Raloxifene (Evista) was also recently proven to decrease breast cancer, and Evista seems to have a lower side effects profile. There are other Selective Estrogen Receptor Molecules coming like PFE's droloxifene (a little behind in the clinicals). LGND has active research on SERMs Tamoxifen variants and metabolites are part of Pharmos pipeline for the future. Pharmos claims a better side effects/safety profile than current tamoxifen. Long way to prove this in humans, lots of resources needed, they need partners for this undertake.